Impact of sapanisertib on 
ALL
LYSED
Pretreatment samples were available from 14 patients enrolled in the study. Immunoblotting revealed that baseline levels of phospho‐ThrIn further analysis, serial samples harvested from five patients prior to therapy and again on Day 8 before drug administration (at the time of daily trough concentrations) were examined for evidence of sapanisertib‐induced changes in mTOR‐mediated phosphorylations. To provide a basis for comparison, the Jurkat ALL cell line and an ALL sample were exposed to sapanisertib ex vivo. These studies indicated that sapanisertib diminished phosphorylation of phospho‐ThrEffect of MLN0128 concentrations on mTOR‐associated phosphorylation in vitro, ex vivo, and in the context of the present trial. (A) Log phase Jurkat cells were treated for 24 h with diluent (0.1% DMSO, lane 1) or sapanisertib at the indicated concentration, lysed, and subjected to immunoblotting for phospho‐Thr